Adaptive Biotechnologies Corporation Common Stock

ADPT trades at a $2.4B valuation while burning cash as an unprofitable biotech—yet RSI sits at 61.3, suggesting momentum traders have already priced in optimism without fundamental earnings support. The 7.02% short interest is modest, indicating skepticism rather than squeeze dynamics. Trading below its 52-week high despite sector recovery signals selective skepticism; the market wants to believe in adaptive immune tech but demands proof. At these valuations, execution becomes everything; missed clinical timelines or competitive setbacks could trigger sharp reversals given the lack of profitability cushion.